Group 1 - AlphaTON Capital Corp. will feature its CEO, Brittany Kaiser, on Schwab Network's Trading 360 to discuss digital assets and their role in modern finance [1][2] - The discussion will emphasize AlphaTON's innovative approach to funding cancer research through blockchain-based asset tokenization, aiming to connect financial innovation with real-world impact [2] Group 2 - AlphaTON Capital is a digital asset treasury company focused on managing a strategic reserve of TON tokens and developing the Telegram ecosystem, providing institutional-grade exposure to the TON ecosystem and Telegram's billion-user platform [3] - The company employs a comprehensive treasury strategy that includes direct token acquisition, validator operations, and strategic investments in decentralized finance protocols, gaming platforms, and business applications [3] - AlphaTON Capital is also involved in drug development, focusing on therapies targeting checkpoint resistance pathways to improve patient quality of life [3]

Core Insights - AlphaTON Capital Corp. is focusing on the integration of digital assets in finance, particularly through blockchain-based asset tokenization to fund cancer research [2][3] - The company is led by CEO Brittany Kaiser and is involved in managing a strategic reserve of TON tokens while developing the Telegram ecosystem [3] Company Overview - AlphaTON Capital is a specialized digital asset treasury company that combines token acquisition, validator operations, and strategic investments to generate sustainable returns for shareholders [3] - The company provides institutional-grade exposure to the TON ecosystem and Telegram's extensive user base while adhering to governance standards of a Nasdaq-listed entity [3] - AlphaTON is also engaged in drug development, focusing on therapies targeting checkpoint resistance pathways to improve patient outcomes [3] Upcoming Events - CEO Brittany Kaiser will appear on Schwab Network's Trading 360 to discuss the role of digital assets in finance and AlphaTON's innovative funding approach for cancer research [1][2]